The Role of Dienogest in the Short-Term Treatment of Endometriosis in Young Women

Shabera Arzoo, Musammat Shamima Akter, N Begum, Nur Jahan Begum, Fatematul Jannat, Kamrun Naher, Munirul Alam
In: Eastern Medical College Journal · 2025 · vol. 10(1) , pp. 45–50 · doi:10.3329/emcj.v10i1.82567 · W4412734386
article OA: hybrid CC0
🔓 Open OA copy Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-08-06 ⓘ

This prospective study found that Dienogest effectively relieved pelvic pain in young women with endometriosis and halted endometrioma growth, with minimal side effects.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-29 · read from full text ⓘ

This prospective observational study evaluated the efficacy and safety of dienogest in 96 young women aged 15–35 diagnosed with endometriosis via ultrasonogram. Participants received 2 mg of oral dienogest daily, with outcomes assessed at one and three months based on pain resolution and changes in endometrioma size. The results indicated significant pain relief for the majority of patients and a favorable safety profile with no major side effects, although the regression of endometriomas was limited. This paper is centrally about endometriosis — specifically the short-term medical management of pelvic pain and cysts in young women using dienogest.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Background: Endometriosis is a long-term, benign, recurrent, debilitating disease experienced by women. Endometriosis associated pelvic pain (EAPP) is the most common complaint reported by patients with the condition. Nearly 70% of females with endometriosis present with EAPP while endometrioma are found in 17-44% of patients. The purpose of the study is to investigate the efficacy and safety of Dienogest as medical therapy to these patients. Materials and Methods: This prospective observational study was carried out in the department of Obstetrics & Gynecology of Eastern Medical College & Hospital from January to December 2023. A total of 96 patients with the age range of 15–35 years with complaints of pain and diagnosed as endometriosis by ultrasonogram were included. All the patients were treated by Dienogest 2 mg orally. The effects of treatment were determined by seeing the resolution of pain and decreasing the size of endometrioma. Patients were followed up in the 1st and 3rd months. Results: Out of 96 patients 72 reported their pain relief within 10-15 days after starting Dienogest. Out of 71 patients who had severe pain at enrollment only 3% had severe pain after 1 month and 1% had severe pain after 3 months of treatment with Dienogest. Successful reduction in endometriotic cyst size (>50%) was seen in 18 (18.75%) at the end of 1 month with Dienogest. At the end of 3 months 24 patients (25.0%) had significant cyst size reduction (>50%) with Dienogest. Complete disappearance of endometriomas was seen in 10 patients (10.41%). No major side effects after 3 months of treatment. Conclusion: Dienogest is a well-tolerated drug for endometriosis. It shows significant relief of pain. However, it was observed that the endometrioma did not grow further, but it did not show significant regression either. It is well tolerated with favorable safety profile. Eastern Med Coll J. July 2025; 10 (1): 45-50
Full text 2,344 characters · extracted from oa-doi-fallback · 4 sections · click to expand

Background

Endometriosis is a long-term, benign, recurrent, debilitating disease experienced by women. Endometriosis associated pelvic pain (EAPP) is the most common complaint reported by patients with the condition. Nearly 70% of females with endometriosis present with EAPP while endometrioma are found in 17-44% of patients. The purpose of the study is to investigate the efficacy and safety of Dienogest as medical therapy to these patients.

Materials and methods

This prospective observational study was carried out in the department of Obstetrics & Gynecology of Eastern Medical College & Hospital from January to December 2023. A total of 96 patients with the age range of 15–35 years with complaints of pain and diagnosed as endometriosis by ultrasonogram were included. All the patients were treated by Dienogest 2 mg orally. The effects of treatment were determined by seeing the resolution of pain and decreasing the size of endometrioma. Patients were followed up in the 1st and 3rd months.

Results

Out of 96 patients 72 reported their pain relief within 10-15 days after starting Dienogest. Out of 71 patients who had severe pain at enrollment only 3% had severe pain after 1 month and 1% had severe pain after 3 months of treatment with Dienogest. Successful reduction in endometriotic cyst size (>50%) was seen in 18 (18.75%) at the end of 1 month with Dienogest. At the end of 3 months 24 patients (25.0%) had significant cyst size reduction (>50%) with Dienogest. Complete disappearance of endometriomas was seen in 10 patients (10.41%). No major side effects after 3 months of treatment.

Conclusion

Dienogest is a well-tolerated drug for endometriosis. It shows significant relief of pain. However, it was observed that the endometrioma did not grow further, but it did not show significant regression either. It is well tolerated with favorable safety profile. Eastern Med Coll J. July 2025; 10 (1): 45-50 259 274 Downloads Published How to Cite Issue Section License Copyright (c) 2025 Eastern Medical College Journal This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosisendometrioma

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK